AU2012298877B2 - Clostridium difficile antibodies - Google Patents

Clostridium difficile antibodies Download PDF

Info

Publication number
AU2012298877B2
AU2012298877B2 AU2012298877A AU2012298877A AU2012298877B2 AU 2012298877 B2 AU2012298877 B2 AU 2012298877B2 AU 2012298877 A AU2012298877 A AU 2012298877A AU 2012298877 A AU2012298877 A AU 2012298877A AU 2012298877 B2 AU2012298877 B2 AU 2012298877B2
Authority
AU
Australia
Prior art keywords
ser
asn
thr
gly
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012298877A
Other languages
English (en)
Other versions
AU2012298877A1 (en
Inventor
Jody Berry
Joyee Antony George
Darrell JOHNSTONE
Bonnie TIGHE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Biosolutions Canada Inc
Original Assignee
Emergent Biosolutions Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Biosolutions Canada Inc filed Critical Emergent Biosolutions Canada Inc
Publication of AU2012298877A1 publication Critical patent/AU2012298877A1/en
Assigned to EMERGENT BIOSOLUTIONS CANADA INC. reassignment EMERGENT BIOSOLUTIONS CANADA INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: CANGENE CORPORATION
Application granted granted Critical
Publication of AU2012298877B2 publication Critical patent/AU2012298877B2/en
Priority to AU2018202199A priority Critical patent/AU2018202199A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2012298877A 2011-08-22 2012-08-22 Clostridium difficile antibodies Ceased AU2012298877B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018202199A AU2018202199A1 (en) 2011-08-22 2018-03-28 Clostridium difficile antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161526031P 2011-08-22 2011-08-22
US61/526,031 2011-08-22
PCT/US2012/051948 WO2013028810A1 (en) 2011-08-22 2012-08-22 Clostridium difficile antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018202199A Division AU2018202199A1 (en) 2011-08-22 2018-03-28 Clostridium difficile antibodies

Publications (2)

Publication Number Publication Date
AU2012298877A1 AU2012298877A1 (en) 2014-03-13
AU2012298877B2 true AU2012298877B2 (en) 2018-01-04

Family

ID=47746848

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012298877A Ceased AU2012298877B2 (en) 2011-08-22 2012-08-22 Clostridium difficile antibodies
AU2018202199A Abandoned AU2018202199A1 (en) 2011-08-22 2018-03-28 Clostridium difficile antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018202199A Abandoned AU2018202199A1 (en) 2011-08-22 2018-03-28 Clostridium difficile antibodies

Country Status (10)

Country Link
US (2) US9505847B2 (enExample)
EP (1) EP2748194A4 (enExample)
JP (1) JP6281163B2 (enExample)
KR (1) KR20140078633A (enExample)
CN (1) CN103917559B (enExample)
AU (2) AU2012298877B2 (enExample)
BR (1) BR112014004162A2 (enExample)
CA (1) CA2845884A1 (enExample)
SG (2) SG10201804809RA (enExample)
WO (1) WO2013028810A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2845884A1 (en) * 2011-08-22 2013-02-28 Cangene Corporation Clostridium difficile antibodies
KR102142261B1 (ko) 2012-03-09 2020-08-11 체에스엘 베링 아게 분비형 면역글로불린을 포함하는 조성물
EP2636684A1 (en) * 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
JP2016501877A (ja) * 2012-11-28 2016-01-21 シーエヌジェー ホールディングス，インコーポレイテッド クロストリジウム・ディフィシルに対する抗体
JP6674888B2 (ja) 2013-03-13 2020-04-01 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
EP4079760A3 (en) * 2013-03-15 2023-01-25 Sanofi Pasteur Inc. Antibodies against clostridium difficile toxins and methods of using the same
CA2939572A1 (en) * 2014-02-19 2015-08-27 Jody Berry Marburg monoclonal antibodies
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
CN109219615B (zh) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
EP3452509A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
JP7293188B2 (ja) * 2017-07-10 2023-06-19 イナート・ファルマ・ソシエテ・アノニム Ｓｉｇｌｅｃ－９中和抗体
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
CN112661849B (zh) * 2020-12-17 2022-05-20 杭州贤至生物科技有限公司 一种艰难梭菌重组蛋白单克隆抗体的制备方法和应用
WO2023113396A1 (ko) * 2021-12-14 2023-06-22 경북대학교 산학협력단 클로스트리듐 디피실 세균을 효과적으로 사멸시키는 재조합 항균 단백질의 용도
CN117720651B (zh) * 2023-12-13 2024-05-31 北京新兴四寰生物技术有限公司 抗艰难梭菌毒素b的单克隆抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087478A1 (en) * 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
US20100233181A1 (en) * 2004-02-06 2010-09-16 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6096716A (en) 1994-12-12 2000-08-01 The Board Of Regents, The University Of Texas System Liposome-mediated transfection of central nervous system cells
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP1150710B1 (en) 1999-02-17 2010-04-21 Csl Limited Immunogenic complexes and methods relating thereto
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
JP2008506683A (ja) 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ， リミテッド 先天免疫応答を誘導するための方法および組成物
KR20100018029A (ko) 2004-07-18 2010-02-16 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제
EP1799262A4 (en) 2004-10-15 2009-10-21 Seattle Genetics Inc ANTI-CD70 ANTIBODIES AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER DISORDERS AND IMMUNE DISORDERS
US7790203B2 (en) 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
BRPI0708771B8 (pt) * 2006-03-10 2021-05-25 Wyeth Corp anticorpos anti-5t4, conjugado de fármaco/ anticorpo para liberação de fármaco, usos dos mesmos e ácido nucléico isolado codificando uma região variável de cadeias pesada e leve anti-5t4
CN103172743B (zh) 2006-12-01 2015-04-08 梅达雷克斯有限责任公司 结合cd22的人抗体及其用途
US7597891B2 (en) 2006-12-13 2009-10-06 Simon Michael R Synthesis of human secretory IgA for the treatment of Clostridium difficile associated diseases
JPWO2008114733A1 (ja) * 2007-03-16 2010-07-01 協和発酵キリン株式会社 抗Ｃｌａｕｄｉｎ−４抗体
CA2705292C (en) * 2007-11-13 2016-06-21 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against tl1a
SG187457A1 (en) 2008-01-11 2013-02-28 Univ Tokyo Anti-cldn6 antibody
US7740844B2 (en) * 2008-04-29 2010-06-22 Taiwan Liposome Co. Ltd Anti-VEGF monoclonal antibody
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
JP5965389B2 (ja) 2010-04-15 2016-08-03 プロゲニクス ファーマシューティカルズ インコーポレーテッドＰｒｏｇｅｎｉｃｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
CA2845884A1 (en) * 2011-08-22 2013-02-28 Cangene Corporation Clostridium difficile antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100233181A1 (en) * 2004-02-06 2010-09-16 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
US20090087478A1 (en) * 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BABCOCK GREGORY J ET AL: " Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters" INFECTION AND IMMUNITY, vol. 74, no. 11, 1 November 2006 (2006-11-01), pages 6339-6347 *

Also Published As

Publication number Publication date
AU2018202199A1 (en) 2018-04-26
EP2748194A4 (en) 2015-01-28
JP2014529610A (ja) 2014-11-13
US20170051047A1 (en) 2017-02-23
WO2013028810A1 (en) 2013-02-28
US20140004118A1 (en) 2014-01-02
CN103917559B (zh) 2018-01-12
HK1199886A1 (en) 2015-07-24
US9994630B2 (en) 2018-06-12
CA2845884A1 (en) 2013-02-28
US9505847B2 (en) 2016-11-29
SG11201400916XA (en) 2014-06-27
NZ622798A (en) 2016-09-30
SG10201804809RA (en) 2018-07-30
JP6281163B2 (ja) 2018-02-21
KR20140078633A (ko) 2014-06-25
BR112014004162A2 (pt) 2018-04-24
AU2012298877A1 (en) 2014-03-13
EP2748194A1 (en) 2014-07-02
CN103917559A (zh) 2014-07-09

Similar Documents

Publication Publication Date Title
AU2012298877B2 (en) Clostridium difficile antibodies
JP6159854B2 (ja) クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
EP3689909A1 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
AU2013352034B2 (en) Antibodies against Clostridium difficile
JP4690196B2 (ja) 復活技術によって生成された炭疽菌毒素に対する中和ヒト抗体
CN114174337A (zh) 针对犬ctla-4的犬源化抗体
EP4257195A2 (en) Anti-cfae antibodies and methods of use
EP3180024B1 (en) Anti-ospa antibodies and methods of use
JP2002515230A (ja) ベロ毒素ｉｉを認識するヒト型化抗体、および該抗体を産生する細胞株
RU2630663C2 (ru) Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний
NZ622798B2 (en) Clostridium difficile antibodies
HK1199886B (en) Clostridium difficile antibodies
HK1179982A (en) Antibodies for the treatment of clostridium difficile-associated infection and disease
HK1179982B (en) Antibodies for the treatment of clostridium difficile-associated infection and disease
AU2013202434A1 (en) Dengue virus neutralizing antibodies and uses thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTORS TO READ GEORGE, JOYEE; BERRY, JODY; JOHNSTONE, DARRELL AND TIGHE, BONNIE

HB Alteration of name in register

Owner name: EMERGENT BIOSOLUTIONS CANADA INC.

Free format text: FORMER NAME(S): CANGENE CORPORATION

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ GEORGE, JOYEE ANTONY; BERRY, JODY; JOHNSTONE, DARRELL AND TIGHE, BONNIE

MK14 Patent ceased section 143(a) (annual fees not paid) or expired